KLK3 and prostate carcinoma: The clinical characteristics showed that the sub-cohort had a higher median PSA at prostate cancer diagnosis as compared to the main cohort (10.6ng/ml vs 8.6ng/ml, P = 0.02); and with a higher frequency of those with Gleason sum ≥8 compared to the main cohort (31.6% vs 20.9%, P = 0.02).